However, HER2-receptor positivity offers opportunities for additional treatment options with anti-HER2-directed therapy, such as trastuzumab and pertuzumab, which selectively binds to HER2 receptors and blocks the signaling and proliferation of tumor cells. This evidence concerns the gene ERBB2 and neoplasm.